Literature DB >> 32901590

Role of Inflammation in the Development of Colorectal Cancer.

Sridhar Muthusami1, Ileng Kumaran Ramachandran2, Kokelavani Nampalli Babu1, Sneha Krishnamoorthy1, Akash Guruswamy3, Lurdes Queimado4, Gautam Chaudhuri5, Ilangovan Ramachandran5.   

Abstract

Chronic inflammation can lead to the development of many diseases, including cancer. Inflammatory bowel disease (IBD) that includes both ulcerative colitis (UC) and Crohnmp's disease (CD) are risk factors for the development of colorectal cancer (CRC). Many cytokines produced primarily by the gut immune cells either during or in response to localized inflammation in the colon and rectum are known to stimulate the complex interactions between the different cell types in the gut environment resulting in acute inflammation. Subsequently, chronic inflammation, together with genetic and epigenetic changes, have been shown to lead to the development and progression of CRC. Various cell types present in the colon, such as enterocytes, Paneth cells, goblet cells, and macrophages, express receptors for inflammatory cytokines and respond to tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and other cytokines. Among the several cytokines produced, TNF-α and IL-1β are the key pro-inflammatory molecules that play critical roles in the development of CRC. The current review is intended to consolidate the published findings to focus on the role of pro-inflammatory cytokines, namely TNF-α and IL-1β, on inflammation (and the altered immune response) in the gut, to better understand the development of CRC in IBD, using various experimental model systems, preclinical and clinical studies. Moreover, this review also highlights the current therapeutic strategies available (monotherapy and combination therapy) to alleviate the symptoms or treat inflammation-associated CRC by using monoclonal antibodies or aptamers to block pro-inflammatory molecules, inhibitors of tyrosine kinases in the inflammatory signaling cascade, competitive inhibitors of pro-inflammatory molecules, and the nucleic acid drugs like small activating RNAs (saRNAs) or microRNA (miRNA) mimics to activate tumor suppressor or repress oncogene/pro-inflammatory cytokine gene expression. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Aptamer; colitis; colorectal cancer (CRC); cytokines; inflammasomes; inflammation; inflammatory bowel diseasezzm321990(IBD); interleukin (IL); microRNA (miRNA/miR); nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB); small activating RNA (saRNA); tumor necrosis factor-alpha (TNF-α); ulcerative colitis (UC)

Year:  2021        PMID: 32901590     DOI: 10.2174/1871530320666200909092908

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  6 in total

1.  Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Authors:  Concetta Saponaro; Annarita Fanizzi; Margherita Sonnessa; Paolo Mondelli; Daniele Vergara; Donato Loisi; Raffaella Massafra; Agnese Latorre; Francesco A Zito; Laura Schirosi
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

2.  Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy.

Authors:  Adit Ben-Baruch
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

3.  Systems pharmacology to reveal multi-scale mechanisms of traditional Chinese medicine for gastric cancer.

Authors:  Lulu Zhang; Yue Xiao; Ruijie Yang; Siyi Wang; ShuangXin Ma; Jianling Liu; Wei Xiao; Yonghua Wang
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

Review 4.  Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy.

Authors:  Ajaz A Bhat; Sabah Nisar; Mayank Singh; Bazella Ashraf; Tariq Masoodi; Chandra P Prasad; Atul Sharma; Selma Maacha; Thasni Karedath; Sheema Hashem; Syed Besina Yasin; Puneet Bagga; Ravinder Reddy; Michael P Frennaux; Shahab Uddin; Punita Dhawan; Mohammad Haris; Muzafar A Macha
Journal:  Cancer Commun (Lond)       Date:  2022-07-05

Review 5.  Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

6.  Methylglyoxal Levels in Human Colorectal Precancer and Cancer: Analysis of Tumor and Peritumor Tissue.

Authors:  Chu-Kuang Chou; Po-Chun Yang; Pei-Yun Tsai; Hsin-Yi Yang; Kun-Feng Tsai; Tsung-Hsien Chen; Kai-Sheng Liao; Chi-Yi Chen; Jen-Ai Lee
Journal:  Life (Basel)       Date:  2021-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.